AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01999764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLT091001
Description: QLT091001 administered orally at multiple time points.
Study NCT01999764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally at multiple time points.
Study NCT00540644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide (Revlimid®)
Description: 25 mg p.o. daily on days 1-21 of each 28 day cycle
Study NCT00540644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg p.o. BID daily on days 1-21 of each 28 day cycle
Study NCT00540644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 50 mg p.o. Q.O.D.
Study NCT01185002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using MgC boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
Study NCT01185002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using Suprep boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
Study NCT01185002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using reduced dose of Suprep boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
Study NCT04020978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Parametric PET/CT
Description: Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
Study NCT02951052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
Study NCT02951052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) tablet
Description: It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose
Study NCT02951052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
Study NCT02951052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study NCT02951052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 NRTIs plus an INI, NNRTI, or PI
Description: Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)
Study NCT04040088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04040088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV
Study NCT04040088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04421963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg olaparib (2×150 mg tablets) twice daily
Study NCT03959527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoliflodacin
Description: Dose: 3g, oral administration
Study NCT03959527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Dose: 500mg, Intra-Muscular (IM) administration
Study NCT03959527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: Dose: 1g, oral administration
Study NCT06433843 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)
Description: 12 weeks inpatient disorder specific psychotherapy
Study NCT04407143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgG test
Description: IgG+ blood test by ELISA method.
Study NCT04716621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention
Description: The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain.
Study NCT04716621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed intervention
Description: Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
Study NCT04404348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
Study NCT04404348 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
Study NCT01135524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
Study NCT01135524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
Study NCT01135524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
Study NCT03306095 — intervention group
Intervention type: OTHER
Intervention: Early refeeding group
Description: Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
Study NCT03306095 — intervention group
Intervention type: OTHER
Intervention: Delayed refeeding group
Description: Food Intake by patient after 4 hours i.e > 4 hours after the EVL procedure
Study NCT03387969 — intervention group
Intervention type: PROCEDURE
Intervention: CSF sample
Description: for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin
Study NCT04371055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day Holter ECG
Description: 7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
Study NCT04371055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor
Description: Continuous rhythm monitoring using an implantable cardiac monitor
Study NCT02790918 — intervention group
Intervention type: OTHER
Intervention: 6MWT
Description: Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
Study NCT02790918 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Study NCT00397189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Prolonged release melatonin 2 mg
Study NCT00397189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo circadin
Description: placebo circadin tablets
Study NCT00925808 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Survey tools and VTE Symptom Follow-up Questionnaire
Study NCT03238794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-En-Y Gastric Bypass
Description: Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
Study NCT03238794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie Diet
Description: Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
Study NCT02027077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
Study NCT02027077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counselling
Description: Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
Study NCT04430088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149
Study NCT04430088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study NCT02904083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self assessment of adherence
Study NCT02904083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self assessment of adherence
Study NCT04371055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
Study NCT00807612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
Study NCT00807612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
Study NCT00807612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
Study NCT00807612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
Study NCT00807612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
Study NCT00766623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat meal
Description: milkshake containing 95g fat
Study NCT00766623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control meal
Description: milkshake comparable with a normal breakfast
Study NCT00056303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
Study NCT00056303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
Study NCT02913781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: polar body removal using zona drilling by laser then suction by injecting pipette
Description: zona drilling with laser followed by polar body removal then ICSI procedure
Study NCT02913781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classic ICSI
Description: Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
Study NCT00608218 — intervention group
Intervention type: DRUG
Intervention: Ciclesonide
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Study NCT02233621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]FES (16α-[18F]Fluoro-17β-estradiol)
Description: PET with \[18F\]FES before coelioscopy
Study NCT03060291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCU-Online, web/ mobile only
Description: Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
Study NCT03060291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FCU-Online, web/ mobile + coach
Description: Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills.
Study NCT02714036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibudilast
Description: Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
Study NCT02714036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
Study NCT02855567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needles
Description: Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
Study NCT02855567 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
Study NCT03864003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care
Description: In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (>50 years) from a rural area that has been identified as under-resourced for hearing health care.
Study NCT03864003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care
Description: In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (>50 years) from a rural area that has been identified as under-resourced for hearing health care.
Study NCT03925181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling Group
Description: All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
Study NCT02372994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loop
Description: Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
Study NCT01018914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT01018914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT01018914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: oral
Study NCT01018914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: oral
Study NCT01817166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Study NCT01817166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Study NCT01817166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Imaging
Description: All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
Study NCT01817166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lumbar puncture
Description: A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
Study NCT01817166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.